We hereby inform that Mr. Vishnu Vasudeva Kuppa has resigned from the position of Company Secretary & Compliance officer of the Company with effect from 23rd April, 2024.

pdf

Bafna Pharmaceuticals Ltd.

22 Apr 2024

76.57

2.35%

Company Update

BAFNA PHARMACEUTICALS LTD. - 532989 - Compliance Certificate Under Regulation 40(9) Of The SEBI (Listing Obligations …

BSE India

We are herewith enclosing the Compliance Certificate issued under Regulation 40(9) of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 for the year ended 31st March, 2024.

pdf

Bafna Pharmaceuticals Ltd.

15 Apr 2024

76.57

2.35%

Company Update

BAFNA PHARMACEUTICALS LTD. - 532989 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

We are herewith enclosing Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for Quarter ended 31st March, 2024.

pdf

Bafna Pharmaceuticals Ltd.

25 Mar 2024

76.57

2.35%

SAST

BAFNA PHARMACEUTICALS LTD. - 532989 - Closure of Trading Window

BSE India

The Trading Window for the designated persons, connected persons, shall remain closed from Sunday, March 31, 2024, up to 48 hours after the declaration of Financial results of the Company by the Board of directors for the quarter and year ending March 31, 2024.

pdf

Bafna Pharmaceuticals Ltd.

14 Feb 2024

76.57

2.35%

Company Update

BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

we have furnished herewith newspaper clippings of Un-audited Standalone Financial Results of the Company for the quarter and nine months ended December 31, 2023, which was approved by the Board in its meeting held on February 12, 2024, and published in the newspapers, namely in Makkal Kural (Tamil edition) and Business Standard (English edition) on Tuesday, February 13, 2024.

pdf

Bafna Pharmaceuticals Ltd.

12 Feb 2024

76.57

2.35%

Result

BAFNA PHARMACEUTICALS LTD. - 532989 - Un-Audited Standalone Financial Results For The Quarter Ended December 31, …

BSE India

we wish to inform that at the meeting of the Board of Directors of the Company held today i.e., February 12, 2024, Monday, the results of the quarter ended on December 31, 2023, duly reviewed by Audit Committee, inter-alia has been considered and approved by the Board of Directors of the Company.

pdf

Bafna Pharmaceuticals Ltd.

02 Feb 2024, 12:21PM

76.57

2.35%

Board Meeting

BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Intimation for Intimation Of Meeting Of Board Of …

BSE India

BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 ,inter alia, to consider and approve A meeting of board of directors of the Company is scheduled to be held on Monday, February 12, 2024, inter-alia, to consider and approve the Un-Audited Standalone Financial Results of the Company for the third quarter of FY24 ended December 31, 2023, together with the 'Limited Review Report' for the said period.

pdf

Bafna Pharmaceuticals Ltd.

11 Jan 2024

76.57

2.35%

Company Update

BAFNA PHARMACEUTICALS LTD. - 532989 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Pursuant to Regulation 74(5) of SEBI(DP) Regulations, 2018, we enclosed herewith a certificate dated January 04, 2024, received from M/s Cameo Corporate Services Limited, the Registrar and Share Transfer Agent of the Company, confirming the dematerialization of share certificate within the prescribed timelines, during the quarter ended December 31, 2023.

pdf

No results found

Is Bafna Pharmaceuticals Ltd. worth buying?

23 Votes:

Buy 69.57%

Sell 21.74%

Hold 8.7%

32.24% Fall from 52W High

High vol. this week

Bafna Pharmaceuticals Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Bafna Pharmaceuticals Ltd. on BSE